Personal CFO Solutions LLC Sells 121 Shares of Amgen Inc. (NASDAQ:AMGN)

Personal CFO Solutions LLC lowered its stake in Amgen Inc. (NASDAQ:AMGN) by 3.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,225 shares of the medical research company’s stock after selling 121 shares during the period. Personal CFO Solutions LLC’s holdings in Amgen were worth $841,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the stock. Atlantic Union Bankshares Corp increased its position in shares of Amgen by 1.7% in the fourth quarter. Atlantic Union Bankshares Corp now owns 3,964 shares of the medical research company’s stock worth $1,033,000 after purchasing an additional 68 shares during the period. Dorsey & Whitney Trust CO LLC grew its position in Amgen by 1.7% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 19,132 shares of the medical research company’s stock valued at $4,987,000 after acquiring an additional 327 shares during the last quarter. Naviter Wealth LLC grew its position in Amgen by 33.7% in the fourth quarter. Naviter Wealth LLC now owns 7,104 shares of the medical research company’s stock valued at $1,852,000 after acquiring an additional 1,791 shares during the last quarter. Rialto Wealth Management LLC bought a new position in Amgen in the fourth quarter valued at about $769,000. Finally, Lifeworks Advisors LLC grew its position in Amgen by 21.2% in the fourth quarter. Lifeworks Advisors LLC now owns 22,705 shares of the medical research company’s stock valued at $5,918,000 after acquiring an additional 3,974 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of recent analyst reports. Piper Sandler lifted their target price on Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. William Blair reiterated an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Jefferies Financial Group reiterated a “buy” rating and issued a $380.00 target price on shares of Amgen in a research report on Tuesday, November 12th. Bank of America lifted their target price on Amgen from $275.00 to $294.00 and gave the company an “underperform” rating in a research report on Wednesday. Finally, Leerink Partners cut their price target on Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $314.95.

Insiders Place Their Bets

In other news, EVP Murdo Gordon sold 8,771 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the completion of the sale, the executive vice president now owns 44,186 shares in the company, valued at $13,025,590.94. The trade was a 16.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is owned by corporate insiders.

Amgen Price Performance

Amgen stock opened at $324.86 on Friday. The stock’s 50 day moving average is $286.14 and its 200 day moving average is $299.69. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The firm has a market cap of $174.52 billion, a P/E ratio of 43.03, a P/E/G ratio of 2.63 and a beta of 0.53. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, research analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 2.93%. Amgen’s payout ratio is currently 126.09%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.